Front-line therapy for nonlocalized diffuse large B-cell lymphoma: What has been demonstrated and what is yet to be established

Ercole Brusamolino, Margherita Maffioli, Maurizio Bonfichi, Umberto Vitolo

Research output: Contribution to journalArticle

Abstract

The field of treatment of diffuse large B-cell lymphoma has been in a continuous flux over the last 10-15 years owing to the introduction of new therapeutic approaches such as dose-dense chemotherapy, monoclonal antibodies and high-dose chemotherapy followed by autologous peripheral blood stem cell transplant. The use of clinical prognostic factors has improved our ability to predict the outcome of these lymphomas; moreover, the gene and protein expression pattern has been shown, at least in the pre-rituximab era, to be an independent and powerful prognostic indicator. This review will focus on results obtained in the last decade by large clinical trials evaluating the first-line therapy in nonlocalized diffuse large B-cell lymphoma; special emphasis will be placed on more mature results that can be indicated as 'standard' therapy. Ongoing studies addressing as yet unanswered or controversial questions will be analyzed, and preliminary data will be critically reviewed.

Original languageEnglish
Pages (from-to)199-210
Number of pages12
JournalFuture Oncology
Volume4
Issue number2
DOIs
Publication statusPublished - Apr 2008

Keywords

  • Autologous stem cell transplantation
  • CHOP
  • Cyclophosphamide
  • Diffuse large B-Cell lymphoma
  • Dose-dense chemotherapy
  • Hydroxydaunorubicin
  • Lymphoma
  • Lymphoma gene profile
  • Prednisone
  • Prognostic factors
  • Randomized clinical trials
  • Rituximad
  • Vincristine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Front-line therapy for nonlocalized diffuse large B-cell lymphoma: What has been demonstrated and what is yet to be established'. Together they form a unique fingerprint.

  • Cite this